Essentials of Model-informed Drug Development in Oncology
Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…
Certara2025 年 10 月 6 日
Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
Certara2025 年 9 月 22 日
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – 2025 年 9 月 17 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…
Certara2025 年 9 月 17 日
Modeling Approaches for Determination of Pharmacokinetics/Pharmacodynamics
Explore insights from Certara experts on how PK/PD modeling streamlines biologic drug development.
Certara2025 年 8 月 5 日
Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling
The Simcyp Simulator receives EMA qualification—the first and only PBPK platform formally qualified for any…
Certara2025 年 8 月 5 日
Mechanistic Models at the Regulatory Frontier: Insights from EMA’s Qualification of the Simcyp® Simulator
The European Medicines Agency (EMA) formally qualified Certara’s Simcyp® Simulator, marking the first and only…
Certara2025 年 8 月 4 日
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
Certara announces that EMA has formally qualified the Simcyp® Simulator for use in regulatory submissions…
Certara2025 年 8 月 4 日
Certara’s Simcyp Educational Webinar Series Part 4: Changes in Drug Absorption after Meals and the Reality of Prediction Using Modeling Approaches [in Japanese]
The Japanese educational webinar series provides essential insights into in vitro data analysis and the…
Certara2025 年 7 月 30 日
